pubmed.ncbi.nlm.nih.gov

The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology? - PubMed

  • ️Fri Jan 01 2021

Review

. 2021 Sep 24;17(4):8-14.

doi: 10.14797/mdcvj.698. eCollection 2021.

Affiliations

Review

The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology?

Tahir Mahmood et al. Methodist Debakey Cardiovasc J. 2021.

Abstract

Despite being largely preventable, atherosclerotic cardiovascular disease (ASCVD) continues to be the leading source of morbidity and mortality worldwide. While the past few decades have seen a substantial reduction in ASCVD mortality, much of this is due to significant improvements in treatment of already manifest disease, with its attendant morbidity and impact on quality of life. Moreover, evidence now suggests that ASCVD mortality in the United States has hit a nadir and is likely to start increasing again. It is now time to shift our attention from intervention to prevention. In this review, we explore the tremendous opportunity to define and implement the discipline of preventive cardiology.

Keywords: atherosclerotic cardiovascular disease; diabetes; dyslipidemia; hypertension; medical subspecialty; obesity; preventive cardiology; risk assessment.

Copyright: © 2021 The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

Figures

Figure 1
Figure 1

The pathways of residual cardiovascular risk, beyond traditional risk factors, with evidence-based therapeutic options. Reprinted with permission. COLCOT: Colchicine Cardiovascular Outcomes Trial; CANTOS: Canakinumab Anti-inflammatory Thrombosis Outcomes Study; JUPITER: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; PEGASUS TIMI 54: Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54; THEMIS-PCI: The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study-PCI; COMPASS: Cardiovascular Outcomes for People Using Anticoagulation Strategies; REDUCE-IT: Reduction of Cardiovascular Events With EPA–Intervention.

Similar articles

Cited by

References

    1. Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021. Feb 23;143(8):e254–e743. doi: 10.1161/CIR.0000000000000950 - DOI - PubMed
    1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019. Sep 10;74(10):e177–e232. doi: 10.1016/j.jacc.2019.03.010 - DOI - PMC - PubMed
    1. Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA, Centers for Disease Control and Prevention (CDC). CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005-2013. MMWR Suppl. 2014. Oct 31;63(4): 3–27. - PubMed
    1. Pantalone KM, Hobbs TM, Chagin KM, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017. Nov 16;7(11):e017583. doi: 10.1136/bmjopen-2017-017583 - DOI - PMC - PubMed
    1. Mattar A, Carlston D, Sariol G, et al. The prevalence of obesity documentation in Primary Care Electronic Medical Records. Are we acknowledging the problem? Appl Clin Inform. 2017. Jan 25;8(1):67–79. doi: 10.4338/ACI-2016-07-RA-0115 - DOI - PMC - PubMed

Publication types

MeSH terms